icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
Gag41RMRyF9TemXx
Listen
